C4 Imaging
Bellaire
About C4 Imaging
C4 Imaging develops innovative medical devices that enable clinicians to personalize patient treatment through accurate image-guided procedures. The company’s core proprietary technology, C4, is a unique magnetic resonance imaging (MRI) agent that has been encapsulated within an implantable, biocompatible shell. C4 Imaging’s first product is the Sirius MRI Marker, which will be used to facilitate seed localization during the treatment of prostate cancer. The Sirius MRI Marker will allow physicians to accurately locate seeds within the complicated anatomy of the prostate and the surrounding critical structures, utilizing a single post-implant MR imaging procedure. C4 Imaging’s goal is to improve quality assurance by allowing post-implant seed localization to be performed with MRI alone, eliminating the need for computed tomography in the assessment of prostate brachytherapy.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $8.7M
- Last round: Series Unknown (Mar 2024)
- Website: c4imaging.com
- Phone: 713-563-2300
Industries & Categories
Hardware, Health Care
Social Profiles
Canonical: https://fsome.com/organization/c4-imaging-57005 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.